Cyclic Peptide Mimetics for Amyloid Fibril Binding Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Amyloidogenic diseases, such as Alzheimer's, Parkinson's, and Huntington's, are characterized by the aggregation of normally soluble proteins into insoluble fibrils, which are resistant to metabolic degradation and contribute to high morbidity and mortality, with existing treatments lacking effective methods to target and destabilize these fibrils.
Innovation Solution
Synthetic cyclic peptide mimetics composed of alternating D- and L-amino acids, including aza- and azasulfuryl-amino acids, are developed to enhance amyloid beta binding activity and stability, potentially destabilizing amyloidogenic aggregates, and can be conjugated with imaging or therapeutic agents like nanoparticles or chelating groups for diagnosis and treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If small molecules are used as receptor ligands, then they can cross the blood-brain barrier, but they lack selectivity and bind to multiple receptors
Solution Approach 1:
The patent changes the molecular parameter from small molecule to large molecule (peptide size range 500-5000 Da), which fundamentally alters the balance between blood-brain barrier penetration and receptor selectivity. The larger peptide size reduces off-target binding while maintaining adequate brain penetration through specific transport mechanisms.
Solution Approach 2:
The patent creates composite peptide structures combining specific amino acid sequences with cyclic constraints and potential conjugation sites, forming a multifunctional molecule that simultaneously achieves brain penetration, high receptor selectivity, and stable pharmacokinetics through the synergistic combination of multiple structural features.
2Manufacturing precision
If peptides are used as receptor ligands, then they provide selectivity, but they are degraded by proteases and have poor pharmacokinetics
Solution Approach 1:
The patent segments the peptide structure into protected cyclic regions and flexible terminal regions, where the cyclic portion provides protease resistance while the terminal portions maintain receptor binding capability. This segmentation allows different regions to fulfill conflicting functional requirements.
Solution Approach 2:
The patent applies parameter changes through cyclization (changing linear peptide to cyclic structure), which fundamentally alters the peptide's resistance to proteolytic degradation while maintaining or enhancing receptor selectivity through constrained conformational states.
3Stability of the object's composition
If cyclic constraints are introduced to peptides, then conformational stability is improved, but synthesis complexity increases
Solution Approach 1:
The patent segments the cyclization strategy into manageable components (e.g., disulfide bridges between specific cysteine residues, head-to-tail cyclization), allowing systematic design and synthesis while maintaining conformational stability. The segmentation approach breaks down the complex cyclization process into standardized modular steps.
Data Source
Figure 1A~1D
Figure 1E
Figure 2A~2C
AI summary
Described herein are synthetic cyclic peptide mimetic s comprising alternating D-amino acids and L-amino acids and amino acid derivatives, such as aza-amino acids and azasulfuryl- amino acids. Optionally, the cyclic peptide mimetic s may be conjugated to another agent via a linker to form cyclic peptide mimetic conjugates. The cyclic peptide mimetic s described herein may be used as diagnostic or therapeutic agents for diagnosis or treatment of amyloidogenic diseases.